I. To perform an exploratory evaluation of pharmacodynamics. II. To study the effects of treatment on exportin 1 (XPO1) expression in peripheral blood mononuclear cells (PBMCs) at day 1 and day 15 of cycle 1, and at the time of progression/relapse.